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Resumen  
 
Introducción: El tratamiento estándar para la terapia neo-adyuvante del Cáncer de Peritoneal 
Primario (PP) y de Ovario (OC) se basa en quimioterapia basadas en platino administradas por vía 
intravenosa (IV) o intraperitoneal, pero esta última está asociada a mayor cantidad de efectos 
adversos grado 3/4.  Para identificar marcadores genéticos que estén asociados a completar los 
ciclos de quimioterapia intraperitoneal, nosotros analizamos polimorfismos de nucleótidos simple 
(SNP) en 4 genes involucrados en el metabolismo de las drogas basadas en platino o taxanos.  
Métodos: Pacientes diagnosticados con cáncer epitelial de ovario o peritoneal primario que sean 
recurrentes o primarios, que hayan sido óptimamente extirpados y que hayan sido tratados con 
quimioterapia IV o IP en la Clínica Mayo (Rochester, MN) entre el periodo de junio del 2007 hasta 
febrero del 2009 fueron reclutados. Se analizó el ADN germinal usando un panel personalizado de 
Ilumina BeadXpress 96-plex. Los genotipos en los SNPs en GSTM1 (N=7), ABCB1 (N=57), 
CYP3A4 (N=7), and CYP2C8 (N=25) fueron correlacionados con completar seis ciclos de 
quimioterapia IP usando regresión logística.  
Resultados: Treinta y siete pacientes fueron incluidos y 16 (43.2%) completaron seis ciclos de 
quimioterapia intraperitoneal. Veintidós de 57 SNPs en el gen ABCB1 fueron asociados con 
completar todos los ciclos (p<0.15), pero el alelo menor A en el rs2229109(missense) llego a tener 
la mayor significancia estadística presentándose en 5 (31.2%) de los pacientes que terminaron 
todos los ciclos de quimioterapia IP, y en solo uno (4.8%) que no completo. Es importante recalcar 
que este último paciente no completo por complicaciones relacionadas al catéter. No se 
encontraron asociaciones significativas en los SNPs de los genes GSTM1. CYP3A4, y CYP2C8. 
No se encontró asociación entre rs2229109 y sobrevivencia. 
Conclusiones: Nuestros resultados sugieren que el SNP rs2229109 (G1199A) en el gen ABCB1 
este asociado con la terminación de los seis ciclos de quimioterapia IP, y potencialmente menos 
toxicidad. Estos pacientes con serían los candidatos ideales para recibir quimioterapia IP, pero se 
necesitan más estudios.  
 
Palabras Claves: Cisplatino, Paclitaxel, ABCB1, Cáncer de Ovario, Quimioterapia Intraperitoneal. 
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ABSTRACT 
 
Introduction: A standard of care (SOC) for adjuvant ovarian (OC) and primary peritoneal (PP) 
cancer treatment is a platinum-based intravenous (IV) or intraperitoneal (IP) chemotherapy 
regimen, but the latter is associated with more frequent grade 3/4 adverse events. To identify 
genetic markers for completion of IP chemotherapy, we analyzed SNPs in four genes, selected for 
their involvement in metabolism of platinum or taxane drugs. 
Methods: Patients who had primary/recurrent stage III/IV optimally debulked epithelial OC or PP 
cancers treated with adjuvant IP and IV chemotherapy at Mayo Clinic (Rochester, MN) between 
January 2007 and February 2009. Germline DNA was analyzed using a custom Illumina 
BeadXpress 96-plex panel. SNPs in GSTM1 (N=7), ABCB1 (N=57), CYP3A4 (N=7), and 
CYP2C8 (N=25) were genotyped and correlated with completion of chemotherapy cycles by linear 
regression.  
Results: Thirty-seven patients were included and 16 (43.2%) completed six IP chemotherapy 
cycles. Twenty-two of 57 ABCB1 SNPs were associated with completion (p<0.15) but the minor 
A allele at rs2229109 (missense) reached the highest significance: present in five (31.2%) who 
completed treatment and only one (4.8%) who did not (p=0.007). However, the latter was due to 
catheter complications. No significant associations were observed for GSTM1. CYP3A4, and 
CYP2C8 SNPs. There were no associations between rs2229109 and overall or progression-free 
survival.  
Conclusion: Our findings suggest that SNP rs2229109 (G1199A) in ABCB1 gene is associated 
with IP chemotherapy completion, and potentially, less toxicity. These patients may be optimal 
candidates for IP chemotherapy and further studies are warranted. 
 
Keywords: Cisplatin, Paclitaxel, ABCB1, Ovarian Cancer, Intraperitoneal Chemotherapy. 
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Introduction 
Ovarian cancer is the most lethal gynecological malignancy, accounting for 22, 280 new cases and 
15,500 deaths in 2012[1].  Standard treatment of advanced ovarian cancer involves cytoreductive 
surgery followed by a platinum- and taxane-based chemotherapy doublet.  Despite advances in 
chemotherapy combinations and schedules, the majority will eventually relapse and die from 
recurrent disease, with five-year survival rates approximately 30-40%[2, 3].  
The pattern of intraperitoneal dissemination seen in patients with ovarian, primary peritoneal, and 
fallopian tube cancers led to the development of intraperitoneal (IP) chemotherapy regimens to 
improve outcomes. IP-containing regimens are associated with significant survival benefits over 
strictly IV chemotherapy [4]. However, the higher incidence of grade 3 and 4 adverse effects have 
impeded acceptance of IP regimens into clinical practice. Identifying predictors of toxicity could 
assist with patient-selection. 
Single nucleotide polymorphisms (SNPs) have been useful in identifying genotypes that are 
associated with metabolism, transportation, and activity of chemotherapy and may contribute to 
differences in therapeutic efficacy and severity of adverse events [5-7]. For instance, the 
intracellular disposition of paclitaxel can be altered by p-glycoprotein pump (P-gp), a 
transmembrane ATP-dependent drug efflux pump and member of the ATP-binding cassette (ABC) 
transporter superfamily. It is encoded by ABCB1 (also known as MDR1). Although polymorphisms 
in ABCB1 are associated with survival [8, 9], presumably through mechanisms involved in 
chemotherapy resistance, less is known about the association between such SNPs and treatment 
toxicity.  For example, a C3435T or G2677T/A genotype is associated with more pronounced 
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neutrophil decline from baseline [5, 10], suggesting greater myelotoxicity in these patients, but 
there was no increased risk of severe febrile neutropenia.  Although C3435T was associated with 
a lower incidence of peripheral neuropathy [10], these findings were not supported by larger 
studies where no association between neurotoxicity or neutropenia was seen in the SCOTROC1 
trial (n=914) or in a retrospective analysis of AGO-OVAR-9 and NSGO-OC9804 (n=119) [11, 
12]. Although the data for genetic polymorphisms and chemotherapy toxicity in ovarian cancer 
patients treated with IV chemotherapy is mixed, no such studies have been performed for patients 
receiving IP chemotherapy, where adverse events are more common [4, 13-18]. 
Cytochrome P450 enzymes, primarily CYP2C8 and CYP3A4, play an important role in paclitaxel 
metabolism and alterations of enzymatic activity could affect drug levels (including metabolites) 
and thus, influence toxicity. The relationship between genetic polymorphisms in ovarian cancer 
patients and IV chemotherapy-related toxicities is also unclear. For instance, CYP2C8*3 was 
initially associated with an 11% reduction of the paclitaxel clearance [19] and increased risk of 
neuropathy [20] while CYP2C8-HapC was associated with treatment-related leukopenia and 
neutropenia [21]. However, larger studies found no association between CYP2C8 or CYP3A4 and 
increased risk for such toxicities [11, 12]. 
Glutathione S transferase (GST) enzymes are comprised of eight distinct classes: alpha, kappa, 
mu, omega, pi, sigma, theta and zeta. GSTM1 encodes a GST belonging to the mu class and 
detoxifies electrophilic compounds such as cisplatin. Although the GSTM1-null genotype has been 
studied in relation to survival [8, 22-25], less is known about the role of GSTM1 regarding 
chemotherapy toxicity. In 104 ovarian cancer patient treated with cisplatin-cyclophosphamide, the 
GSTM1-null genotype was associated with a lower risk of cytopenia and neuropathy relative to the 
wild-type genotype [6].  
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In light of the discrepant data regarding SNPs and chemotherapy toxicities in ovarian cancer 
patients treated with IV chemotherapy and the paucity of similar data for IP chemotherapy, we 
investigated the association between SNPs encoded by common carboplatin- or paclitaxel-
metabolizing genes. We hypothesized that single nucleotide polymorphism in these genes may 
predict tolerability of six IP cycles of chemotherapy and be a useful indicator of toxicity.  
Therefore, we analyzed 96 SNPs in ABCB1, CYP2C8, CYP3A4 and GSTM1 from 37 patients 
receiving intraperitoneal chemotherapy for epithelial ovarian or primary peritoneal cancer. 
Methods 
Patient Population 
Patients with primary or recurrent epithelial ovarian or primary peritoneal cancer undergoing 
primary or secondary debulking surgery at the Mayo Clinic (Rochester, MN) between January of 
2007 and February of 2009 were eligible for this study. All patients received at least one cycle of 
intraperitoneal chemotherapy. A cycle was defined as IV paclitaxel (135mg/m2) on day one, IP 
cisplatin (100mg/m2) on day two, and IP paclitaxel (60mg/ m2) on day eight. For patients to be 
defined as a completing intraperitoneal chemotherapy, they should have finished six cycles of this 
regimen at full or reduced doses. Patients that had five cycles or less of IP chemotherapy were 
classified as incomplete. Histologic features, surgical outcomes, and recurrence status of each 
patient was abstracted via the electronic medical record system in accordance with the Mayo Clinic 
Institutional Review Board 
DNA extraction and genotyping 
Patient germline DNA was extracted from pre-treatment peripheral blood using the Gentra 
Autopure LS Purgene (Gentra, Minneapolis,MN) salting out method. Samples were barcoded to 
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protect patient privacy and stored at a - 20°C.  A custom Illumina BeadXpress 96-plex panel was 
used to genotype single nucleotide polymorphism in GSTM1 (N=7), ABCB1 (N=57), CYP3A4 
(N=7), and CYP2C8 (N=25).  
SNP Selection 
To create ld tagSNPs for the 4 candidate genes, we used genotypes from the the genome-wide 
genotyping projects Hapmap Phase II (http://www.hapmap.org) and Perlegen (www.perlegen.com 
- URL no longer valid as company is out of business).  We also used genotypes from the gene 
resequencing programs:  Seattle SNPs (http://pga.mbt.washington.edu/) and NIEHS SNPs 
(http://egp.gs.washington.edu/).  To determine the Hapmap and Perlegen SNPs for each of the 
candidate genes, we picked SNPs 5kb upstream and 5 kb downstream of each gene.  Our gene and 
SNP coordinates were based on RefSeq release 29 (NCBI build 36), and dbSNP build 129.  If the 
gene had been resequenced in Seattle SNPs or NIEHS SNPs, we used genotypes from those 
sources as well.   
To pick ld tagSNPs, we ran ldSelect [26] on each gene for each genotype source (Hapmap, 
Perlegen, Seattle, NIEHS) for the Caucasian samples in those public sources.  We used an r^2 of 
0.95 and a minor allele frequency (maf) cutoff of 0.05.  To determine the best source of genotypes 
for each gene, we chose the source with the higher number of ld bins for the Caucasian samples 
after bins were removed that didn't have a tagSNP with an assay score of 0.4 or greater.  If 2 
sources (e.g. Hapmap, Seattle SNPs) had the same number of bins, we used Hapmap as the best 
source because of its higher number of samples (60 unrelated Caucasian samples).  Hapmap was 
chosen as best source for 3 of the genes and NIEHS was chosen for CYP3A4.  To pick the best 
tagSNP for each LD bin, we used the SNPPicker software [27] LdSelect often gives multiple 
choices of tagSNPs for a given bins but not all tagSNPs have the same design probability or 
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possible functional relevance.  SNPPicker picks the best tagSNP for each bin, optimizing 
constraints such as assay score and functional relevance. It also allows multiple tagSNPs for bins.  
To reduce the probability of failure, we picked 2 tagSNPs where possible while 3 were chosen for 
bins with size of 30 or greater.  All tagSNPs met the minimum Illumina assay score of 0.4. 
In addition to tagSNPs, we included potentially functional SNPs that had not been already chosen 
as tagSNPs.  This included missense SNPs with maf (as reported by Illumina) in a Caucasian 
population > 0.  We also included synonymous, 5’ upstream (within 5kb of candidate gene), 5’ 
UTR, 3’ UTR, 3’ downstream (within 5kb of candidate gene) SNPs with maf >= 5% 
Statistical analysis 
Association between SNPs and the number of cycles of chemotherapy was performed with linear 
regression using an additive model for each SNP.  
Results 
Thirty-seven patients diagnosed with ovarian or primary peritoneal cancer were included in this 
study and successfully genotyped.  Patient characteristics are shown in Table 1. The majority of 
patients were diagnosed with ovarian cancer (75.6%) and the remaining with primary peritoneal 
cancer (24.3%). The most common histological subtype was serous (78.2%), followed by 
endometrioid and clear cell. All patients underwent primary or secondary optimal surgical 
debulking at Mayo Clinic between January of 2007 to February of 2009. Till June of 2012, 56.7% 
of the thirty-seven patients have recurred, 37.8% are disease free, and 5.4% are lost to follow-up. 
Sixteen patients (43.2%) out of the thirty-seven patients enrolled in this study were able to 
complete the six cycles of IP chemotherapy, while twenty-one (56.7%) had to abandon this 
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regimen due to adverse events.  ABCB1, GSTM1, CYP2C8 and CYP3A4 were genotyped for SNPs 
associated with completion of IP chemotherapy (Table 2). SNPs in ABCB1 demonstrated 
statistically significant associations with the number of chemotherapy cycles. The minor allele 
G1199A (S400N) at rs2229109 was significantly associated with completion of the six cycles of 
IP chemotherapy (p=0.007) and was present in 5 of 16 patients (31.2%) completing IP 
chemotherapy (Table 3). Only one patient with G1199A was unable to complete IP chemotherapy 
but this was attributed to catheter infection rather than chemotherapy toxicity. 
Other ABCB1 SNPs associated with the number of intraperitoneal chemotherapy cycles were 
intronic: rs17327442 (p=0.028), rs6961665 (p= 0.093), rs13233308 (p=0.093) and rs4148732 
(p=0.062)(Table 2). These SNPs are close to each other and to rs2229109 in ABCB1 (Figure 1). 
Out of the 57 SNPs analyzed in ABCB1, 22 SNPs also had some degree of association with the 
number of chemotherapy cycles (p<0.15) (Table 4 and Figure 1).  No association between 
rs2229109 (G1199A) and progression free survival or overall survival was seen in this study. 
No statistically significant association was seen between GSTM1, CYP3A4 and CYP2C8 and the 
number of intraperitoneal chemotherapy cycles. 
Discussion 
 
To our knowledge, this is the first study to report the association of single nucleotide 
polymorphisms in key genes involved in the transport and metabolism of platinum – taxane 
chemotherapies in ovarian/primary peritoneal cancer patients treated with intraperitoneal 
chemotherapy.  Ninety-six SNPs in four different genes involved in the metabolism of platinum 
and taxane agents were genotyped from thirty-seven patients. Results showed that a minor A allele 
(G1199A) at SNP rs2229109 in ABCB1 was more likely to complete all cycles of intraperitoneal 
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chemotherapy than those who did not carry this SNP (p=0.007).   We could not find any association 
between CYP3A4, CYP2C8 and GSTM1 and completion of chemotherapy. 
Although larger studies have not shown an association between ABCB1 polymorphisms and IV 
chemotherapy-related toxicity, the different pharmacokinetics of IP chemotherapy may obviate the 
applicability of these data to patients presented herein. Indeed, the IP route achieves much higher 
peritoneal-to-plasma AUC ratios: carboplatin (12-fold), cisplatin (10-18 fold), and paclitaxel 
(1000-fold) [28-30]. Since expression of ABCB1 is high in normal gastrointestinal (liver and bowel 
lumen) tissues [31-33], drainage of fluid from the visceral peritoneum into the portal vein subjects 
xenobiotics to hepatic first-pass metabolism [34] and altered function of this gene could impact 
systemic bioavailability and toxicity. Indeed, G1199A is a missense allele that, when expressed in 
recombinant epithelial cells (ABCB1-1199A), confers greater ability to efflux fluorescently tagged 
substrates in the basal-to-apical direction [35]. This phenomenon is substrate-specific since 
vincristine and vinblastine, but not doxorubicin, exhibit greater permeability in ABCB1-1199A 
cells [36]. Although the permeability of paclitaxel was not directly studied, ABCB1-1199A cells 
were more resistant to paclitaxel, suggesting G1199A alters permeability of paclitaxel in normal 
cells and may alter bioavailability. Thus, G1199A (rs2229109) may be associated with completion 
of IP chemotherapy cycles by virtue of lower systemic chemotherapy levels and thus, less toxicity. 
Although there was no association with survival, these data are consistent with larger studies [37]. 
Although no associations were seen with GSTM1, CYP2C8 and CYP3A4 polymorphisms and 
completion of IP chemotherapy, these data are consistent with larger studies showing no increased 
risk for toxicities [11, 12]. The absence of significant association between these genes and 
completion of IP platinum/taxane chemotherapy may reflect a lack of understanding of the 
intracellular mechanisms of metabolism of these compounds via the intraperitoneal route.  
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Intraperitoneal platinum-taxane chemotherapy for ovarian, primary peritoneal, and fallopian tube 
cancer has demonstrated improved survival over IV-alone chemotherapy and on January 5, 2006, 
the National Cancer Institute (NCI) announced a recommendation to consider combination IV/IP 
chemotherapy regimens for all optimally debulked patients with good performance status [38]. 
However, a survey of surgical and medical oncologists suggests the clinical practice has been slow 
to implement such therapy[39]. Although 77% of respondents discussed IP chemotherapy with 
patients, survey response rates were low among surgical (24%) and medical (3%) oncologists; as 
such, the true frequency of IP-chemotherapy counseling may be much lower than reported.    One 
of the main reasons is catheter-related complications but also, higher incidences of hematologic 
and gastrointestinal adverse events have been a hindrance. For these reasons, an international 
consensus did not support making IP chemotherapy the new standard of care [40]. Predictors of IP 
chemotherapy tolerability may enable clinicians to select optimal patients for treatment. 
 
In conclusion, this study provides the first evidence that single nucleotide polymorphisms in 
ABCB1 are associated with completion of the six cycles of intraperitoneal chemotherapy, and 
possibly less serious adverse events for this regimen. These findings will need to be reproduced in 
a larger population set, preferably with case-control or matched cohort designs to eliminate 
confounders and allow us to assess whether SNP rs2229109 impacts clinical outcomes.  This 
knowledge will help us determine which subset of patients will be the most suitable candidates for 
intraperitoneal chemotherapy.  
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TABLES 
Table 1. - Patient Characteristic. 
 Patients (N) (%) 
Age (years)     
   <50 6 16.2 
   50-59 8 21.6 
   60-69 14 37.8 
   >70 9 24.3 
      
Primary Tumor Site     
   Ovary 28 75.6 
   Peritoneal 9 24.3 
      
Histological Subtypes     
   Serous 29 78.2 
   Endometrioid 6 16.2 
   Clear Cell 2 5.4 
      
Post-Surgery tumor volume     
   Optimal 37 100 
   Suboptimal 0 0 
      
No. of Cycles of IP 
Chemotherapy 
    
      6 cycles 16 43.2 
      <5 cycles 21 56.7 
      
Recurrence Status     
   Recurred or deceased 21 56.7 
   No recurrence 14 37.8 
   Unknown 2 5.4 
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Table 2. - List of genes analyzed. 
Name Chr GeneID Description SNPs (N) P<0.05* 
ABCB1 7 5243 ATP-binding cassette, sub-family B, member 1 57 Yes 
CYP2C8 10 1558 Cytochrome P450, family 2, subfamily C, polypeptide 8 25 No 
CYP3A4 7 1576 Cytochrome P450, family 3, subfamily A, polypeptide 4 7 No 
GSTM1 1 2944 Glutathione S Transferase M1 7 No 
*P values reflect SNP level significance.  
 
 
Table 3. - ABCB1 [rs2229109] genotype in our patient population. 
Allele No. Of Cycles N (%) Total N (%) 
G/A  6 5 (83.3)   
  ≤5 1 (16.6)   
      6 (16.2%) 
        
G/G 6 11 (35.4)   
  ≤5 20 (64.5)   
      31 (83.7%) 
 
Table 4. - Most significant SNPs associated with completion of IP chemotherapy. 
Gene RSID P Value Base Substitution Variant Type 
ABCB1 RS2229109 0.007 A/G missense 
 RS6961665 0.093 A/C intron 
 RS17327442 0.028 A/T intron 
 RS4148732 0.063 A/G intron 
 RS13233308 0.093 C/T intron 
 RS998671 0.802 A/G 3'downstream 
 RS6946119 1 C/T 3'downstream 
 RS7802783 0.802 C/T 3'downstream 
 RS1055302 0.802 A/G 3'downstream 
 RS3842 0.802 A/G 3'UTR 
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 RS17064 0.916 A/T 3'UTR 
 RS2235048 0.154 C/T intron 
 RS1045642 0.154 A/C/T synonymous 
 RS6949448 0.391 C/T  intron 
 RS2373589 0.96 A/G intron 
 RS7787082 0.96 A/G intron 
 RS2032581 - A/G missense 
 RS11983225 0.744 C/T intron 
 RS11760837 0.744 C/T intron 
 RS12720066 0.582 G/T intron 
 RS4148737 0.443 A/G intron 
 RS4728700 0.129 C/T intron 
 RS1922242 0.443 A/T intron 
 RS2235046 0.129 A/G intron 
 RS2091766 0.443 C/T intron 
 RS2235033 0.093 C/T intron 
 RS2032588 0.258 C/T intron 
 RS1128503 0.129 C/T synonymous 
 RS3789244 0.129 A/C intron 
 RS1922240 0.259 C/T intron 
 RS1922241 0.259 A/G intron 
 RS2235023 0.258 A/G intron 
 RS4148734 0.259 C/T intron 
 RS1202169 0.129 A/G intron 
 RS6950978 0.259 A/T intron 
 RS12334183 0.337 C/T intron 
 RS10260862 - C/G intron 
 RS10264990 0.107 C/T intron 
 RS1989830 0.891 C/T intron 
 RS13226726 0.666 C/T intron 
 RS1202172 0.891 G/T intron 
 RS1202184 0.203 A/G intron 
 RS1211152 0.969 G/T intron 
 RS17327624 0.161 G/T intron 
 RS13229143 0.627 C/G intron 
 RS12535512 0.528 C/T intron 
 RS2188526 0.5 A/G intron 
 RS3789243 0.369 C/T intron 
 RS1858923 0.5 C/T intron 
 RS2888599 0.43 A/G intron 
 RS9282564 0.835 A/G missense 
 RS2214102 0.993 A/G 5'UTR 
 RS3213619 0.43 C/T 5'UTR 
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 RS4728709 0.326 A/G intron 
 RS10246878 0.526 A/G intron 
 RS10267099 0.526 A/G intron 
  RS6972098 0.326 C/T 5'upstream 
 
FIGURES 
Figure 1.- 
 
Figure 1. a) ABCB1 is located on chromosome 7 in the q21.12 region. The five most significant SNPs associated 
with completion of IP chemotherapy, rs2229109, rs6961665, rs17327442, rs4148732 and rs13233308, are located 
1.6kpb, 31.5kpb, 21 kpb and 10.9 kpb away from each other, respectively. b) Linkage Disequilibrium plot of ABCB1 
was created using Haploview v4.2. Standard color scheme: white =(D′<1, LOD<2), blue =(D′=1, DOD<2), shades 
of pink/red =(D′<1, LOD ≥ 2), bright red =(D′=1, LOD ≥2). The numbers inside the squares represent the D′ values. 
 
 
 
